ProCE Banner Activity

Novel RET Inhibitor BOS172738 in RET-Altered Cancers Including RET Fusion–Positive NSCLC and RET Mutation–Positive Medullary Thyroid Cancer

Slideset Download
Conference Coverage
BOS127238, a novel, highly selective RET inhibitor, was associated with a manageable safety profile and preliminary efficacy in a phase I study in RET-altered solid tumors.

Released: June 08, 2021

Expiration: June 07, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme